TCM
SAGE

Tributary Capital Management’s Sage Therapeutics SAGE Stock Holding History

Tributary Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,800
Closed -$655K – 204
2022
Q1 		$655K Buy
19,800
+300
+2% +$11.3K 0.05% 165
2021
Q4 		$830K Buy
19,500
+9,500
+95% +$398K 0.06% 154
2021
Q3 		$443K Buy
+10,000
New +$459K 0.03% 199
2021
Q2 		– Sell
-15,300
Closed -$1.15M – 232
2021
Q1 		$1.15M Buy
+15,300
New +$1.25M 0.09% 139

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tributary Capital Management's SAGE Position: Q2 2022 in Review

Tributary Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 19,800 shares — an estimated $655K sold.

Tributary Capital Management first reported a position in SAGE in Q1 2021 and held it in 4 quarters. The position peaked at $1.15M in Q1 2021. 209 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

  • Tributary Capital Management reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Tributary Capital Management sold 19,800 Sage Therapeutics shares in Q2 2022, an estimated $655K.
  • Tributary Capital Management first reported a position in Sage Therapeutics in Q1 2021 and held it in 4 quarters.
  • Tributary Capital Management's Sage Therapeutics position peaked at $1.15M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Tributary Capital Management's 13F filing for Q2 2022, filed 19 Jul 2022.